Cargando…

National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study

No studies of the current status of treatment options are available for ankylosing spondylitis (AS) patients in South Korea. This study assesses the current status of AS treatment trends using a nationwide database. This study was conducted using a Korean National Health Insurance System (KNHIS) dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jin-Sung, Hong, Jae-Young, Kim, Hak-Kyu, Koo, Bongmo, Kim, Sang-Hee, Kwon, Yong-Chol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537903/
https://www.ncbi.nlm.nih.gov/pubmed/33021982
http://dx.doi.org/10.1371/journal.pone.0240155
_version_ 1783590758670925824
author Park, Jin-Sung
Hong, Jae-Young
Kim, Hak-Kyu
Koo, Bongmo
Kim, Sang-Hee
Kwon, Yong-Chol
author_facet Park, Jin-Sung
Hong, Jae-Young
Kim, Hak-Kyu
Koo, Bongmo
Kim, Sang-Hee
Kwon, Yong-Chol
author_sort Park, Jin-Sung
collection PubMed
description No studies of the current status of treatment options are available for ankylosing spondylitis (AS) patients in South Korea. This study assesses the current status of AS treatment trends using a nationwide database. This study was conducted using a Korean National Health Insurance System (KNHIS) dataset from 2006 to 2016. We randomly extracted 50% of the total number of patients registered as As patients in the KNHIS. The distribution of the number of patients according to age and gender was analyzed each year. The types and combination methods of drugs used during the study period were estimated yearly. Between 2006 and 2016, the number of AS patients increased linearly by an average of 9% annually, 6372 in 2006 to 15188 in 2016. The study found that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) was the most commonly prescribed pharmacological treatment option, followed by disease-modifying anti-rheumatic drugs (DMARDs) and then biologics. Biologics such as tumor necrosis factor alpha (TNF-α) inhibitors increased from 10% to 35% consistently for 10 years. In terms of combination therapy, DMARDs + NSAIDs accounted for almost 90% of treatments in 2006, but decreased by 65% in 2016. The use of biologics and NSAIDs increased from 3% to 28%. Prescriptions for dual therapies and mono therapies largely dominated prescription habits, accounted for up to approximately 80% of treatments. Among 10- to 14-year-old patients, there was no triple therapy, dual and triple therapies decreased gradually for those 60 and older, and the ratio of conservative treatments has increased. This study shows how South Korea reflects changes in AS treatment trends, along with the emergence of TNF-α inhibitors that are effective in treating AS. Research on clinical outcomes for AS treatments will be needed on following these drug changes.
format Online
Article
Text
id pubmed-7537903
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-75379032020-10-19 National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study Park, Jin-Sung Hong, Jae-Young Kim, Hak-Kyu Koo, Bongmo Kim, Sang-Hee Kwon, Yong-Chol PLoS One Research Article No studies of the current status of treatment options are available for ankylosing spondylitis (AS) patients in South Korea. This study assesses the current status of AS treatment trends using a nationwide database. This study was conducted using a Korean National Health Insurance System (KNHIS) dataset from 2006 to 2016. We randomly extracted 50% of the total number of patients registered as As patients in the KNHIS. The distribution of the number of patients according to age and gender was analyzed each year. The types and combination methods of drugs used during the study period were estimated yearly. Between 2006 and 2016, the number of AS patients increased linearly by an average of 9% annually, 6372 in 2006 to 15188 in 2016. The study found that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) was the most commonly prescribed pharmacological treatment option, followed by disease-modifying anti-rheumatic drugs (DMARDs) and then biologics. Biologics such as tumor necrosis factor alpha (TNF-α) inhibitors increased from 10% to 35% consistently for 10 years. In terms of combination therapy, DMARDs + NSAIDs accounted for almost 90% of treatments in 2006, but decreased by 65% in 2016. The use of biologics and NSAIDs increased from 3% to 28%. Prescriptions for dual therapies and mono therapies largely dominated prescription habits, accounted for up to approximately 80% of treatments. Among 10- to 14-year-old patients, there was no triple therapy, dual and triple therapies decreased gradually for those 60 and older, and the ratio of conservative treatments has increased. This study shows how South Korea reflects changes in AS treatment trends, along with the emergence of TNF-α inhibitors that are effective in treating AS. Research on clinical outcomes for AS treatments will be needed on following these drug changes. Public Library of Science 2020-10-06 /pmc/articles/PMC7537903/ /pubmed/33021982 http://dx.doi.org/10.1371/journal.pone.0240155 Text en © 2020 Park et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Park, Jin-Sung
Hong, Jae-Young
Kim, Hak-Kyu
Koo, Bongmo
Kim, Sang-Hee
Kwon, Yong-Chol
National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study
title National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study
title_full National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study
title_fullStr National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study
title_full_unstemmed National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study
title_short National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study
title_sort national pharmacological treatment trends for ankylosing spondylitis in south korea: a national health insurance database study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537903/
https://www.ncbi.nlm.nih.gov/pubmed/33021982
http://dx.doi.org/10.1371/journal.pone.0240155
work_keys_str_mv AT parkjinsung nationalpharmacologicaltreatmenttrendsforankylosingspondylitisinsouthkoreaanationalhealthinsurancedatabasestudy
AT hongjaeyoung nationalpharmacologicaltreatmenttrendsforankylosingspondylitisinsouthkoreaanationalhealthinsurancedatabasestudy
AT kimhakkyu nationalpharmacologicaltreatmenttrendsforankylosingspondylitisinsouthkoreaanationalhealthinsurancedatabasestudy
AT koobongmo nationalpharmacologicaltreatmenttrendsforankylosingspondylitisinsouthkoreaanationalhealthinsurancedatabasestudy
AT kimsanghee nationalpharmacologicaltreatmenttrendsforankylosingspondylitisinsouthkoreaanationalhealthinsurancedatabasestudy
AT kwonyongchol nationalpharmacologicaltreatmenttrendsforankylosingspondylitisinsouthkoreaanationalhealthinsurancedatabasestudy